CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04969315
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:26:39.947651+00:00
Published At: 2025-04-02T00:00:00+00:00
Record Updated At: 2025-04-02
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Renal Cell Cancer", "Castrate Resistant Prostate Cancer", "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Colorectal Cancer (CRC)", "Endometrial Cancer", "Ovarian Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-04-02"
protocolSection.identificationModule.nctId: "NCT04969315"
protocolSection.identificationModule.officialTitle: "Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.